Vistagen secures new patents for PH80 migraine treatment

Vistagen has expanded its global intellectual property (IP) portfolio with the receipt of multiple new patents for its PH80, a neuroactive pherine nasal spray developed for the treatment of migraine.

The company has previously received patents in the US and from the European Patent Office.

The patents are expected to be in force until 2040, subject to extensions.

The new patents have been granted by IP Australia, the Hong Kong Intellectual Property Department, the Japan Patent Office and the Mexican Institute of Industrial Property.

In Australia, the company’s PH80 secured a Notice of Allowance. It obtained Patent No 40068177 in Hongkong, and Patent No 7476229 in Japan. PH80 also secured notice of allowance in Mexico.

PH80 has a unique mechanism of action that targets neurocircuitry without requiring systemic absorption or direct neuronal activity in the brain.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

<!–

–>

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vistagen is developing the spray as a hormone-free option for managing women’s health issues including vasomotor symptoms associated with menopause, premenstrual dysphoric disorder, dysmenorrhea and migraine.

Pherines represent a new class of compounds aimed at treating psychiatric and neurological disorders through neurocircuitry-focused mechanisms.

The neuroscience-focused biopharmaceutical company is engaged in the development and commercialisation of therapies for psychiatric and neurological disorders.

Its pherine drug candidates have demonstrated favourable safety profiles in all studies completed.

In 2023 the company obtained a Notice of Allowance from the Canadian IP Office for a patent related to the use of AV-101 in Parkinson’s disease (PD) patients.

The treatment reduces the sudden uncontrolled movements, or dyskinesia, caused by using the PD medication levodopa.

https://www.shutterstock.com/image-photo/senior-woman-using-cpap-machine-stop-737747287

<!– –>


This article was originally published here.